Study to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver Fibrosis

Open to people ages 18 years and up

• Able to understand and comply with study procedures and give written informed consent
• Age ≥18 years
• NAS ≥4 with a score of at least 1 in each component of the NAS (steatosis, lobular inflammation, and ballooning) at Visit 2 liver biopsy, or a historical liver biopsy performed within 24 weeks of randomization
• Fibrosis stage of 1 or greater and below 4 on NASH CRN (Clinical Research Network) fibrosis staging system at Visit 2 liver biopsy, or a historical liver biopsy performed within 24 weeks of randomization
• Meet all inclusion criteria outlined in clinical study protocol

• Participation in another clinical trial involving an investigational agent within 30 days prior to signing the Informed Consent Form (ICF) for this study
• Ongoing or recent consumption of Greater than moderate amounts of alcohol as defined in clinical study protocol
• Evidence of other forms of chronic liver disease as defined in clinical study protocol
• Does not meet any other exclusion criteria outlined in clinical study protocol